{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kilaru AS"],"funding":["NIDA NIH HHS"],"pagination":["154-157"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8608552"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["47"],"pubmed_abstract":["<h4>Objective</h4>To determine the rate at which commercially-insured patients fill prescriptions for naloxone after an opioid-related ED encounter as well as patient characteristics associated with obtaining naloxone.<h4>Methods</h4>This is a retrospective cohort study of adult patients discharged from the ED following treatment for an opioid-related condition from 2016 to 2018 using a commercial insurance claims database (Optum Clinformatics® Data Mart). The primary outcome was a pharmacy claim for naloxone in the 30 days following the ED encounter. A multivariable logistic regression model examined the association of patient characteristics with filled naloxone prescriptions, and predictive margins were used to report adjusted probabilities with 95% confidence intervals.<h4>Results</h4>21,700 patients had opioid-related ED encounters during the study period, of which 1743 (8.0%) had encounters for heroin overdose, 8825 (40.7%) for overdose due to other opioids, 5400 (24.9%) for withdrawal, and 5732 (26.4%) for other opioid use disorder conditions. 230 patients (1.1%) filled a prescription for naloxone within 30 days. Patients with heroin overdose (2.6%; 95%CI 1.7 to 3.4), recent prescriptions for opioid analgesics (1.4%; 95%CI 1.1 to 1.7), recent prescriptions for buprenorphine (1.9%; 95%CI 1.0 to 2.9), and naloxone prescriptions in the prior year (3.3%; 95%CI 1.8 to 4.8) were more likely to obtain naloxone. The rate was significantly higher in 2018 [1.9% (95%CI 1.5 to 2.2)] as compared to 0.4% (95%CI 0.3 to 0.6) in 2016.<h4>Conclusions</h4>Few patients use insurance to obtain naloxone by prescription following opioid-related ED encounters. Clinical and policy interventions should expand distribution of this life-saving medication in the ED."],"journal":["The American journal of emergency medicine"],"pubmed_title":["Naloxone prescriptions following emergency department encounters for opioid use disorder, overdose, or withdrawal."],"pmcid":["PMC8608552"],"funding_grant_id":["P30 DA040500"],"pubmed_authors":["Gupta R","Delgado MK","Lowenstein M","Liu M","Kilaru AS","Meisel ZF","Perrone J"],"additional_accession":[]},"is_claimable":false,"name":"Naloxone prescriptions following emergency department encounters for opioid use disorder, overdose, or withdrawal.","description":"<h4>Objective</h4>To determine the rate at which commercially-insured patients fill prescriptions for naloxone after an opioid-related ED encounter as well as patient characteristics associated with obtaining naloxone.<h4>Methods</h4>This is a retrospective cohort study of adult patients discharged from the ED following treatment for an opioid-related condition from 2016 to 2018 using a commercial insurance claims database (Optum Clinformatics® Data Mart). The primary outcome was a pharmacy claim for naloxone in the 30 days following the ED encounter. A multivariable logistic regression model examined the association of patient characteristics with filled naloxone prescriptions, and predictive margins were used to report adjusted probabilities with 95% confidence intervals.<h4>Results</h4>21,700 patients had opioid-related ED encounters during the study period, of which 1743 (8.0%) had encounters for heroin overdose, 8825 (40.7%) for overdose due to other opioids, 5400 (24.9%) for withdrawal, and 5732 (26.4%) for other opioid use disorder conditions. 230 patients (1.1%) filled a prescription for naloxone within 30 days. Patients with heroin overdose (2.6%; 95%CI 1.7 to 3.4), recent prescriptions for opioid analgesics (1.4%; 95%CI 1.1 to 1.7), recent prescriptions for buprenorphine (1.9%; 95%CI 1.0 to 2.9), and naloxone prescriptions in the prior year (3.3%; 95%CI 1.8 to 4.8) were more likely to obtain naloxone. The rate was significantly higher in 2018 [1.9% (95%CI 1.5 to 2.2)] as compared to 0.4% (95%CI 0.3 to 0.6) in 2016.<h4>Conclusions</h4>Few patients use insurance to obtain naloxone by prescription following opioid-related ED encounters. Clinical and policy interventions should expand distribution of this life-saving medication in the ED.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Sep","modification":"2025-04-04T10:44:12.196Z","creation":"2025-04-04T10:44:12.196Z"},"accession":"S-EPMC8608552","cross_references":{"pubmed":["33812332"],"doi":["10.1016/j.ajem.2021.03.056"]}}